Turnover
≈ €29,000 estimated
The accounts state no turnover.
ORTHOPHAR
Lifetime
18 annual accounts with figures on one time axispeak €328,302 (2015)
€3,807▼ 76.8%
lowest -€1,261 (2007)
€2,109▼ 88.3%
peak €257,259 (2025)
€257,259▲ 0.8%
€1,497▼ 91.0%
Board2 names since 2013
2 directorsISALA and 1 other
Owners
50%ISALA
Documentsfilings and deeds
29-01-2026on the last day
2025micro format
Gross margin from €16,380 to €3,807Result from €18,082 to €2,109Debts from €16,696 to €1,497
Key points
from the 2025 annual accountsFilings
18 annual accounts since 2007
Two of the last ten came late. The 2019 accounts came latest: 1 day after the end of the period.
Position in the sector
99.4%
Higher solvency than 95% of companies in pharmaceuticals. Sector median 35.8% · 75 companies.
Checked score
96
Excellent
Financially stronger than 69% of micro companies in pharmaceuticals (NACE 21)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 152 companies (NACE 21, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024highest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025lowest value
08-2025: < 0.1%● unchanged vs 07-2025lowest value
09-2025: < 0.1%● unchanged vs 08-2025lowest value
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Liquidity: current ratio 179.77, cash €199,728
Equity €257,259 (99.4% of total assets)
Founded in 2006
Size: total assets €258,756
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 90% of them on solvency, 96% on liquidity, 42% on profitability and 49% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 29-06-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 17,041 companies had the same profile as ORTHOPHAR has now. Each dot stands for 43 companies, two years later.
94.4%
were still trading
4.9%
stopped another way
0.5%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of ORTHOPHAR itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,041 companies, not a prediction for ORTHOPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €24,000 on 30-day terms is acceptable
Short-term debt is 0.6% and cash 77.2% of total assets. 0.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 29-06-2025 was due by 29-01-2026 and was filed on 29-01-2026, 0 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
on the day
2024
1 day late
2023
on the day
2022
3 days early
2021
2 days early
2020
11 days early
2019
1 day late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 2 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 29-06-2026 is due by 29-01-2027. Nothing is late today. The company usually files around 29 January (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
29-06-2026 year end10-11-2026 today29-01-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0879711212
Changes of role: Sodofin (director) and Isala (director)
Permanent representatives: FLAMENT Dominic Marcel Arnould and VANNESTE Alain Werner · Director discharge: Sodofin · Director discharge: Isala · Gazette deed
Registered office moved from Rollegem to Bellegem
New registered office: Kreupelstraat 50, 8510 Bellegem · Previous registered office: Munkendoornstraat 188, 8510 Rollegem · Permanent representative: Dominic Flament · Board meeting of 14-11-2020 · Gazette deed
First establishment
Kreupelstraat 50, Kortrijk
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ORTHOPHAR Kortrijk | €258,756 | €3,807 | 99.4% | - |
| HUVESEARCH Pelt | €95,955 | €1,033 | 59.9% | - |
| RTLC Brussels | €107,167 | -€66 | 61.9% | - |
| OROPHARMA Deinze | €352,437 | €20,797 | 56.0% | - |
| WANDJI PHARMA INTERNATIONAL Tournai | €357,118 | €30,451 | 25.2% | - |
| EURANDLAB Charleroi | €27,845 | €7,398 | 87.8% | - |
| FYTOBELL Hasselt | €122,152 | -€55,562 | -322.9% | - |
These companies have the same main activity as ORTHOPHAR: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €27,800 and €357,000, founded between 1987 and 2019.
Official details
Source: KBO- Status
- Active since 02-03-2006Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 7 others
- Establishment unit
- 2.153.657.8418510 Kortrijk, since 22-05-2006
- Financial year end
- 29 June
- Peppol
- Reachable since 17-12-2025
Annual accounts to 29-06-2025
- €258,756▼ 4.8%
- Filing
- Filed on 29-01-2026, on the last day of the filing period
Insights on ORTHOPHAR
ORTHOPHAR files the micro format. That format states no turnover. The gross margin rose from €2,966 in 2007 to €3,807 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ORTHOPHAR
- What is the company number of ORTHOPHAR?
- The company number of ORTHOPHAR is 0879.711.212. The VAT number is the same number with BE in front: BE 0879.711.212.
- Where is ORTHOPHAR based?
- The registered office is at Kreupelstraat 50, 8510 Kortrijk.Company details
- What does ORTHOPHAR do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
- What is the legal form of ORTHOPHAR?
- ORTHOPHAR is a private limited company (BV).
- When was ORTHOPHAR founded?
- ORTHOPHAR was founded on 02-03-2006.
- Is ORTHOPHAR still active?
- Yes, ORTHOPHAR is an active enterprise in the KBO register.
- What is the turnover of ORTHOPHAR?
- The turnover in financial year 2025 is ≈ €29,000. This figure is estimated from the gross margin of €3,807 and 6,299 comparable companies of the same size. It probably lies between €13,000 and €69,000. It is a rough estimate.Financials
- Is ORTHOPHAR profitable?
- In financial year 2025, ORTHOPHAR made a profit of €2,109.
- Where can I find the annual accounts of ORTHOPHAR?
- ORTHOPHAR filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ORTHOPHAR due?
- ORTHOPHAR must file the annual accounts for financial year 2026 by 29-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.